Navigation Links
Brain Cancer Vaccine's Immune Response Key to Outcomes
Date:7/15/2008

Tumor-altering shot, already in trials, lengthens survival, study finds

TUESDAY, July 15 (HealthDay News) -- An in-trial dendritic cell vaccine that fights malignant brain tumors called glioblastoma multiforme (GBM) may help boost a patient's immunity response and improve the outcome, a new report says.

An article in the July 15 issue of Cancer Research says this would mark the first time a tumor-altering therapeutic intervention would have shown such promise.

"Fifty-three percent of patients in our study exhibited a significant vaccine-enhanced immune response. Compared to non-responders or those with limited responses, the vaccine responders had significantly longer times to tumor progression and longer survival," one the article's authors, Cedars-Sinai's Department of Neurosurgery Chairman Dr. Keith L. Black, said in a news release issued by the Los Angeles-based medical center.

The study also supports past findings that the dendritic cell vaccination can work well with chemotherapy to improve treatment. The researchers reported that the time to tumor progression greatly increased when chemotherapy followed vaccination, compared to vaccination alone.

"No other vaccine trial in cancer patients has shown the kind of progressive correlation between immune responses and clinical outcomes that we found," the article's first and corresponding author, Christopher J. Wheeler, a research scientist at the Maxine Dunitz Neurosurgical Institute, said in the same news release.

These results, centered on 32 patients enrolled in a Phase II clinical trial, included 17 patients having significant positive response after three vaccinations, while 15 showed no such responsiveness. Average time to tumor progression (based on when tumor volume increased by about 25 percent on MRI scans) was 308 days among responders, compared to 167 days for non-responders.

The average length of survival was about 21 months among responders, about 14 months for non-responders. Forty-one percent of vaccine responders survived at least two years, though, compared with only 7 percent of non-responders.

All those in the trial showed a longer time to progression and longer time of survival, on average, than patients undergoing standard treatment without vaccination.

More information

The Brain Tumor Society has more about brain cancer.



-- Kevin McKeever



SOURCE: Cedars-Sinai Medical Center, news release, July 15, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Draining away brains toxic protein to stop Alzheimers
2. Vision restoration therapy shown to improve brain activity in brain injured patients
3. Clinical depression linked to abnormal emotional brain circuits
4. Brain imaging reveals breakdown of normal emotional processing
5. Brain cells work differently than previously thought
6. Vaccine Stops Alzheimers Brain Tangles
7. Research may unlock mystery of autisms origin in the brain
8. Scientists Spot Brains Free Will Center
9. Free will takes flight: how our brains respond to an approaching menace
10. Alcoholics With Cirrhosis Have More Brain Damage
11. Brain Lesions Predict MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... Bill ... 2017 collaboration with the American Heart Association; “Howe” Healthy is Your Heart Drawing ... stay healthy and active. Each year, Bill Howe Plumbing, Heating & Air receives over ...
(Date:1/19/2017)... MD (PRWEB) , ... January 19, 2017 , ... Sales ... six new clients into the US market. , Over the past 20 years SFI ... past 4 weeks SFI has launched six new clients into the US market. ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Breast Surgery Symposium, a conference where hundreds of surgeons from over fifteen different ... Covering topics from cosmetic breast augmentation to breast reconstruction for breast ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting of a new ... the benefits of fidgeting to relieve stress and anxiety. No one was more ... Ink Pen had just completed a successful Kickstarter campaign raising $67,000 on the popular ...
(Date:1/18/2017)... ... January 18, 2017 , ... Visually learn facts and ... OTC antiperspirant, Certain Dri. , Excessive sweating and hyperhidrosis are common conditions that ... infographic to explain the seven types of hyperhidrosis. This visual creates awareness about ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017  Abaxis, Inc. (NasdaqGS: ABAX ), ... and consumables for the medical and veterinary markets worldwide, ... results for the third quarter fiscal year 2017, ended ... p.m. ET on Thursday, January 26, 2017.  The Company ... year 2017 after the market closes on Thursday, January ...
(Date:1/19/2017)... -- Shire plc (LSE: SHP, NASDAQ: ... Drug Administration (FDA) has acknowledged receipt of the Class ... SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. SHP465 ... Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected to provide ... designated Prescription Drug User Fee Act (PDUFA) action date. ...
(Date:1/19/2017)... January 19, 2017 While ... serious about reducing the FDA,s regulatory strictness as ... the medical drug industry, many of the leading ... clinical trials and development of advanced drug treatments ... with recent developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology: